References

1. Marez, D.; Legrand, M.; Sabbagh, N.; Lo Guidice, J.M.; Spire, C.; Lafitte, J.J.; Meyer, U.A.; Broly, F. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997, 7, 193-202.

2. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Homepage. http://www.imm.ki.se/ CYPalleles/ (accessed March 2004).

3. Flockhart, D.A. Cytochrome P450 drug interaction table. http://medicine.iupui.edu/flockhart/ (accessed March 2004).

4. Scordo, M.G.; Spina, E.; Facciola, G.; Avenso, A.; Johansson, I.; Dahl, M.L. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology 1999, 147 (3), 300-305.

5. Brosen, K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther. Drug Monit. 1996, 18 (4), 393-396.

6. Hasler, J.A.; Estabrook, R.; Murray, M.; Pikuleva, I.; Waterman, M.; Capdevila, J.; Holla, V.; Helvig, C.; Falck, J.R.; Farrell, G.; Kaminsky, L.S.; Spivack, S.D.; Boitier, E.; Beaune, P. Human cytochromes P450. Mol. Aspects Med. 1999, 20, 1-137.

7. Stiiven, T.; Griese, E.U.; Kroemer, H.K.; Eichelbaum, M.; Zanger, U.M. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 1996, 6, 417-421.

8. Raimundo, S.; Fischer, J.; Eichelbaum, M.; Griese, E.U.; Schwab, M.; Zaner, U.M. Elucidation of the genetic basis of the common intermediate metabolizer phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000, 10, 577-581.

9. Lovlie, R.; Daly, A.K.; Molven, A.; Idle, J.R.; Steen, V.M. Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett. 1996, 392, 30-34.

10. Lovlie, R.; Daly, A.K.; Matre, G.; Molven, A.; Steen, V.M. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: A role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 2001, 11 (1), 45-55.

11. Allorge, D.; Harlow, J.; Boulet, O.; Hayhurst, G.P.; Chowdry, J.; Roth, E.; Crewe, K.; Lo-Guidice, J.M.; Lhermitte, M.; Broly, F.; Tucker, G.T.; Ellis, S.W. In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism. Pharmacogenetics 2001, 11 (8), 739-741.

12. Müller, B.; Zopf, K.; Bachofer, J.; Steimer, W. Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin. Chem. 2003, 49 (1o), 16241631.

13. Steen, V.M.; Andreassen, O.A.; Daly, A.K.; Tefre, T.; Borresen, A.L.; Idle, J.R.; Gulbrandsen, A.K. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995, 5, 215-223.

14. Stuven, T.; Griese, E.U.; Kroemer, H.K.; Eichelbaum, M.; Zanger, U.M. Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 1996, 6, 417-421.

15. Stamer, U.M.; Bayerer, B.; Wolf, S.; Hoeft, A.; Stuber, F.

Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin. Chem. 2002, 48 (9), 1412-1417.

16. Schaeffeler, E.; Schwab, M.; Eichelbaum, M.; Zanger, U.M. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Human Mutat. 2003, 22, 476-485.

17. Sachse, C.; Brockmoller, J.; Bauer, S.; Roots, I. Functional significance of a C! A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 1999, 47, 445-449.

18. Chida, M.; Yokoi, T.; Fukui, T.; Kinoshita, M.; Yokota, J.; Kamataki, T. Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn. J. Cancer Res. 1999, 90, 899-902.

19. Sachse, C.; Bhambra, U.; Smith, G.; Lightfoot, T.J.; Barrett, J.H.; Scollay, J.; Garner, R.C.; Boobis, A.R.; Wolf, C.R.; Gooderham, N.J. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: Allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br. J. Clin. Pharmacol. 2003, 55, 68-76.

20. Popp, J.; Messner, B.; Steimer, W. High-speed genotyping of CYP1A2*1F mutation with fluorescent hybridization probes using the LightCyclerTM. Pharmacogenomics 2003, 4 (5), 643-646.

Getting Started With Dumbbells

Getting Started With Dumbbells

The use of dumbbells gives you a much more comprehensive strengthening effect because the workout engages your stabilizer muscles, in addition to the muscle you may be pin-pointing. Without all of the belts and artificial stabilizers of a machine, you also engage your core muscles, which are your body's natural stabilizers.

Get My Free Ebook


Post a comment